Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.
Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedNew dates and a specific address in Groningen, Netherlands have been added, while several earlier dates and a related FDA section have been removed.SummaryDifference0.7%
- Check15 days agoChange DetectedThe website has added FDA Safety Alerts and Recalls in the new revision v2.11.2, replacing the previous revision v2.11.0.SummaryDifference0.2%
- Check22 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in study record information.SummaryDifference0.7%
- Check30 days agoChange DetectedClinicalTrials.gov has acknowledged delays in displaying study record information and has updated to revision v2.10.5, replacing the previous v2.10.3.SummaryDifference0.6%
- Check44 days agoChange DetectedThe website has been updated to version 2.10.3, with the notable removal of FDA Safety Alerts and Recalls from the previous version 2.10.2.SummaryDifference0.2%
- Check65 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.1%
Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.